about
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationRational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastomaAffinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MiceIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaPotential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancerEngineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Hallmarks of response to immune checkpoint blockade.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine GliomasThe Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer TherapyDisruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsCombination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapiesB cells and tertiary lymphoid structures promote immunotherapy responseThe human tumor microbiome is composed of tumor type-specific intracellular bacteria
P50
Q24623215-BD75959A-DEF4-4188-85A6-03140A935E60Q29615032-587422FA-29D4-4B8F-BAFC-48ED6C8B6824Q35741739-A97233DB-922A-4511-B7DD-ACE9E2C9482EQ36028047-8460B0D2-9F01-4EC3-ADA3-E9331B22A15FQ36651344-7DE2F2A7-634E-450C-B63B-365009082CF3Q37392729-55E1507C-49A5-4D7F-A0DF-A111F60DB43FQ37711887-3DC342E3-9ABB-4721-B86D-96C134EDD2F2Q38618945-D20F7CC4-E599-4258-9CB1-D088F25218F0Q39212469-BF64B0BE-C421-42DB-9AED-8B02F3CF11FBQ41078811-7A6C0FDE-2C4C-4BB6-AA8B-17F314DD6505Q47447695-E2B708DB-B713-46D1-A5E6-19BD7B52146EQ47958949-E5F93D64-3C75-4495-B282-48E386BF3484Q50532989-3069E66D-2821-49CF-9F0B-B5D236A13794Q52964477-F6759710-9B5E-479E-9435-0D6AEC760B11Q57300937-29DFF5E0-EFF1-4D9F-AD55-2B7D43B8CADDQ58579512-DD562F66-0F72-4A71-978E-D7D293815A91Q58889356-BD87B6CC-4FDF-4421-BB8D-2D0C59CD3C84Q90856677-BDF50657-C361-40F1-A583-EA91EF4B473CQ92669559-4ADE2E03-BDC8-45A5-836E-80326833F6F0Q95936132-1E823503-F897-43BC-A05D-61E0CDBD63B8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandria P Cogdill
@ast
Alexandria P Cogdill
@en
Alexandria P Cogdill
@es
Alexandria P Cogdill
@nl
type
label
Alexandria P Cogdill
@ast
Alexandria P Cogdill
@en
Alexandria P Cogdill
@es
Alexandria P Cogdill
@nl
prefLabel
Alexandria P Cogdill
@ast
Alexandria P Cogdill
@en
Alexandria P Cogdill
@es
Alexandria P Cogdill
@nl
P108
P106
P108
P1153
34871668300
P31
P4012
P496
0000-0001-8917-9462